A retrospective study demonstrated that GLP-1 receptor agonist use before pregnancy corresponded with lower risks for ...
Northwestern University researchers have identified structural features in engineered cell receptors that correlate with ...
Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.
The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.
Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback